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Abstract
Introduction. Spinal muscular atrophy (SMA) is one of the most common genetic causes of death in infants 
due to a mutation of the motor neuron 1 (SMN1) gene. The SMN1 gene encodes for the multifunctional SMN 
protein. SMN has been shown to be implicated in pre-mRNA splicing, mRNA transport and translational con-
trol. Also other mRNA processing proteins, such as GLE1, Marten (MART3) and Fused in Sarcoma (FUS), 
have been linked to neurodegenerative diseases. The aim of the study was to determine the expression of SMN, 
GLE1, MART3 and FUS genes in cell lines of the fibroblasts derived from SMA patients and normal controls.
Material and methods. Total RNA was extracted from purchased fibroblasts acquired from three SMA type I 
patients and fibroblasts of three age-matched healthy controls. The RNA was then subjected to qPCR analysis 
using primers specific for the GLE1, MART3, FUS and SMN1 genes vs. GAPDH as internal control gene. 
Results. SMN1 mRNA levels were at least ×10 lower in fibroblasts of SMA patients compared to controls. Gle1 
and MART3 gene expression was ×2 downregulated whereas FUS mRNA levels appeared to be ×3 upregulated 
in SMA cells when compared to controls. We found a high correlation between FUS gene expression level to the 
SMN1 at gene expression level of fibroblast cell lines of SMA type I patients (r = 0.994, p < 0.0001).
Conclusions. Our preliminary data show an intriguing expression profile of Gle1, MART3 and FUS genes in 
SMA, and suggest a critical role of FUS protein in the SMA pathogenesis. (Folia Histochemica et Cytobiologica 
2018, Vol. 56, No. 4, 215–221)
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Introduction 
Spinal muscular atrophy (SMA) is a neurodegen-
erative disease primarily affecting the lower motor 
neurons, leading to weakness, atrophy and eventually 
paralysis. Patients suffering from SMA typically die 
before the age of two years [1]. To date, evidence 
shows that mutations of the motor neuron 1 (SMN1) 
gene is the main cause of pathology. The SMN1 gene 
encodes for a multifunctional SMN protein [1].The 
earliest reported and best characterized role of SMN1 
is in pre-mRNA splicing, but it has also been implicat-
ed in mRNA transport and translational control [1].
The clinical severity of SMA can vary widely, rang-
ing from death in infancy to disability in adulthood. 
The disease has been classified into: Type I, Type II, 
Type III and Type IV, depending on the clinical 
manifestations and age at onset of disease [2]. SMA 
type 1 starts to affect neonates up to the age of six 
months. It has been reported that SMN1 gene that 
encrypts the SMN protein and plays a vital role in 
216 Aziza Alrafiah et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2018
10.5603/FHC.a2018.0022
www.fhc.viamedica.pl
transcriptional regulation, telomerase regeneration 
and cellular trafficking, is either deleted or missing [2]. 
Although the genetic basis of SMA is well understood, 
the underlying mechanism of pathology of the remains 
unclear [2, 3]. Moreover, it is not yet fully understood 
how the lack of SMN leads to SMA, and why is it 
affecting solely the spinal motor neurons. There is 
an urgent need to further investigate the mechanism 
and molecular component of the disease, which could 
open new therapeutic avenues. 
Mounting research evidence suggests that SMN 
performs a significant function both within pre-mR-
NA splicing and in the axon’s function of trafficking 
mRNA-binding proteins and their target mRNAs 
[3, 4]. The challenge currently facing researchers is to 
understand why a defect in the spliceosome machinery 
used by all cells should selectively affect the motor 
neurons [3, 4]. 
Research has shown several genetic predisposi-
tions common between neurodegenerative diseases. 
For example, mutations to chromosome 9 hexanu-
cleotide repeat72 (C9ORF72), transactive response 
DNA binding protein (TARDBP) and Charged Mul-
tivesicular Body Protein 2B (CHMP2B) have been 
implicated in both frontotemporal lobar degeneration 
(FTLD) and amyotrophic lateral sclerosis (ALS) [5]. 
Mutations to the ataxin-2 gene (ATXN2) have been 
reported in ALS and spinocerebellar ataxia type 2 
(SCA2) [6]. Furthermore, many neurodegenerative 
disease-related genetic risk factors have roles in RNA 
processing, such as FUS, TARDBP, C9orf72, angio-
genin (ANG), ataxin-2 (ATXN2), matrin 3 (MART3), 
huntingtin, and SMN1 [6–11]. This underscores the 
importance of efficient RNA-processing for a healthy 
nervous system. 
In this paper, we selected three genes: GLE1 
(RNA export mediator) [12], FUS (Fused in Sarco-
ma) [13] and MART3 (Mammalian retrotransposon 
transcript) [14], which are known to be involved in 
other neurodegenerative diseases, with the aim of 
examining them for differential expression between 
normal human fibroblasts and primary fibroblast cul-
tures derived from the skin of SMA patients. GLE1 
encodes for a protein that is involved in RNA export, 
and mutations to this gene have been associated with 
lethal congenital contracture syndrome 1 (LCCS1) 
[11, 15, 16]. FUS mutations have been associated with 
few juvenile ALS cases [11]. MART3, meanwhile, is 
a DNA and RNA binding protein with diverse RNA 
processing functions. It has been reported to interact 
with TDP-43 [5]. Mutations in the MART3 gene have 
been linked to some ALS cases [7]. 
To date, clinical trials have very limited success in 
reporting an effective treatment of neurodegenerative 
disorders. However, a lot of effort has been made in 
trying to understand the molecular mechanism of 
these diseases in order to target different therapeu-
tic approaches that are based on the evidence that 
SMN1 expression levels correlate with SMA severity 
[4]. Therapeutic development is focused mainly on 
increasing SMN protein levels using gene therapy 
based on SMN1 replacement by viral vectors [17]. 
Other therapeutic trials focus on cell replacement 
and neuroprotection [17, 18]. 
This case-control study was undertaken to investigate 
the association between the expression of the SMN1 
gene which controls the fate of mRNA, and other 
mRNA processing genes such as GLE1, MART3 and 
FUS that have been linked to other motor neuron 
diseases.
Material and methods
Cell lines. Human fibroblasts of three healthy subjects 
(Cat. No: GM05565, GM00498 & AG08498) and three 
age-matched type I SMA patients (3 years old, male) were 
purchased from the Coriell Institute for Medical Research 
(Cat. No GM03813, GM03814 & GM03815). Cells were 
cultured in tissue culture flasks T75 in minimal essential 
medium (MEM) (M2279, Sigma-Aldrich, St. Louis, MO, 
USA) containing 10% fetal bovine serum (FBS) (FB1001, 
Biosera, Kansas City, KS, USA), 1% penicillin-streptomy-
cin (17-602E, Lonza, Basel, Switzerland), 1% MEM Eagle 
Vitamin Mixture (13-607C, Lonza), 1% sodium pyruvate 
(Sigma) and 0.1% uridine (50 mg/mL, Sigma). 
RNA extraction and quantitative polymerase chain reaction 
(qPCR). Tissue samples were harvested in 1 ml GIBCO BRL 
TRIZOL (Cat. No. 15596) per 50 to 100 mg tissue, using 
a glass-TEFLON homogenizer (Thomas Scientific, Swedes-
boro, NJ, USA). After 5 min incubation at room temperature 
(RT) of the homogenized samples chloroform was included 
with a portion of 0.2 ml for every 1 ml of TRIZOL Reagent. 
The mixture was shocked actively followed by centrifugation 
for 15 min at 4°C at 12,000 rpm. 
RNA was collected from the top aqueous stage followed 
by mixing with 0.5 ml isopropanol in new Eppendorf flask 
and incubated for 10 min at RT, then re-centrifuged for 
20 min at 13,300 rpm at 4°C.
The RNA pellet was washed with 75% alcohol and dried 
at RT then thawed in diethyl pyrocarbonate (DEPC)-treat-
ed water. The RNA was quantified using the NanoDrop 
spectrophotometer ND2000 (Labtech, East Sussex, UK). 
After that following the standard Quick-Start supplied 
protocol, RNA 700 ng/microL was reversibly transcribed to 
complimentary DNA (cDNA) using the QuantiTect Reverse 
Transcription Kit (Cat No./ID: 205310, Qiagen, Hilden, 
Germany), Real-time PCR was performed in a MX3000P 
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RT-PCR System (Stratagene, San Diego, CA, USA) to 
evaluate the expression levels of SMN1, MART3, GLE1 and 
FUS, with the levels being normalized against glyceraldehyde 
phosphate dehydrogenase (GAPDH) (n = 3). 
The Primer sequences used for each gene were as 
follows: 
SMN1 cDNA was amplified using the primer pair: SMN1 
human F 5’-GAGGAGCAAAATCTGTCC-3’, SMN1 
human R 5’-TTTCCAGGAGACCTGGAG-3’; GLE11 
human F 5’CTTTGACAAGATCCACAG, GLE1 human 
R5’ CACCATGAAGCAGCATTC; 
MART3 human 5’GATGACTTGAAAGTAGGG, MART3 
human R5’GTGTGACACCAAGATAAG;
FUS human 5’AAACAAGAAAACGGGACAGC, FUS 
human R5’GGTCTCATTTGCTACTCGCC.
The primer pair b-GAPDH mRNA, F– 5’ GGAAGCT-
CACTGGCATGGC3’, and the R– 5’ TAGACGGCAGGT-
CAGGTCCA 3’ was used as the housekeeping transcript.
All primers were added to a final concentration of 100 nM 
with approximately 12.5 ng of cDNA per well. Real-time 
polymerase chain reaction (RT-PCR) reaction was per-
formed in the volume of 13 µl with a Brilliant II SYBR 
Green QPCR master mix (Stratagene) for 40 cycles of 2-step 
qPCR protocol. Using the Delta-Delta-Ct (DDCt) method 
the relative expression was calculated by ABI PRISM 7700 
Sequence Detection System protocol (Applied Biosystems, 
Foster City, CA, USA). Each sample was run in triplicate. 
Statistical analysis. All data are presented as mean ± SD. 
Each gene was analyzed using GraphPad Prism v. 7.02 software 
(Graphpad, San Diego, CA, USA). Differences were analyzed 
by the paired t-test to contrast every single SMA fibroblast line 
with the control fibroblast cell line and by one-way ANOVA 
with p less than 0.05 regarded as statistically significant.
Results
All experiments were performed in triplicate (n = 3). 
SMN1 gene expression in fibroblasts  
of SMA patients
SMN1 gene expression levels were at least × 10 lower 
and were even barely detected in the SMA fibroblasts 
compared to control fibroblasts samples (Fig. 1A, 
p < 0.0001).
MART3 gene expression in SMA fibroblasts
MATR3 expression levels in the SMA fibroblasts were 
found to be × 2 lower as compared to the control 
fibroblasts samples (Fig. 1B, p < 0.005). 
A
C
B
D
0.0
0
0.0
0.0
0.5
1
0.5
0.5
1 0.
2
1 0.
1 0.
1 5.
3
4
1 5.
1 5.
FB-control
FB-control
FB-control
FB-control
****
***
**
**
SMN1
FUS
MART3
GLE1
FB-SMA
FB-SMA
FB-SMA
FB-SMA
G
e
n
e
 e
x
p
re
s
s
io
n
G
e
n
e
 e
x
p
re
s
s
io
n
G
e
n
e
 e
x
p
re
s
s
io
n
G
e
n
e
 e
x
p
re
s
s
io
n
Figure 1. The expression of the studied genes was determined by qPCR in SMA fibroblasts of spinal muscular atrophy patients 
(FB-SMN) and control fibroblasts (FB-Control). A. SMN gene expression. The bar chart shows that the SMN1 expression 
(Y axis) was absent in SMA fibroblasts (FB-SMA) and present in the control samples (FB-Control); ****p < 0.0001 (paired 
t-test, n = 3). Error bars represent the standard error of the mean. B. MART3 gene expression. It was down-regulated in SMA 
fibroblasts in relation to control fibroblasts; **p < 0.005 (paired t-test, n = 3). C. FUS gene expression. It was up-regulated 
in SMA fibroblasts (***p < 0.001 (paired t-test, n = 3). D. GLE1 gene expression. It was down regulated in SMA fibroblasts 
(**p < 0.005 two-way ANOVA, n = 3).
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FUS gene expression in SMA fibroblasts
Interestingly, FUS expression underwent a × 3 upregu - 
lation in the SMA fibroblasts compared to control 
fibroblasts samples (Fig. 1C, p < 0.0001). 
GLE1 gene expression in SMA fibroblasts
GLE1 expression was down regulated in SMA fibro-
blasts, approximately × 2 of its expression in control 
fibroblasts (Fig. 1D, p < 0.005). 
Associations between expression of FUS and 
MART3 genes and SMN1 gene expression
Multiple regression analysis was used to test if the 
SMN1 gene expression at mRNA level significantly 
predicted gene level expression of GLE1, MART3 
and FUS proteins. 
Single linear regression test was performed to 
assess correlation between FUS and SMN1 genes 
and indicated that there was very high correlation 
coefficient R2 of 0.994, p < 0.0001 (Fig. 2A).
Single linear regression test was performed to 
assess correlation between MART3 and SMN1 genes 
expression. There was a moderate positive correlation 
R2 of 0.592, p =0.005 (Fig. 2B). 
Single linear regression test was performed to 
assess correlation between GLE1 and SMN1 genes 
expression. We found that there was a weak correla-
tion R2 of 0.354, p = 0.01.
Discussion
The mechanism by which SMN1 gene alteration 
leads to SMA pathological state has yet not been 
completely explained. In the current research, we 
aimed to contribute to the current body of knowl-
edge of SMA and increase our understanding of the 
pathogenesis of the disease. This study reports on 
the differential expression of four genes involved in 
mRNA processing, SMN1, MART3, GLE1 and FUS 
genes, in SMA patients fibroblast cell line compared 
to the age-matched control cell line. Our results 
showed a correlation between genetic risk factors of 
neurodegenerative diseases: FUS, MATR3 and GLE1 
which are nuclear proteins that are involved in RNA 
processing. FUS protein binds to DNA and regulates 
transcription [19, 20]. MATR3 has several functions in 
post-transcriptional RNA processing [15]. Interaction 
between FUS and MATR3 has been reported recently 
[21], whereas GLE1 is involved in mRNA export and 
translation [12, 22]. 
Considering the functions of the four genes of in-
terest in this study, i.e. FUS involved in transcription, 
SMN and MATR3 involved in post-transcriptional 
RNA processing and GLE1 involved in mRNA ex-
port, our results show that FUS gene responds to the 
absence of SMN level by increased expression of its 
mRNA while genes encoding MATR3 and GLE1 
decrease their expression what is suggestive of the 
interaction between these proteins. 
Particularly, we documented differential ex-
pression of these genes in the SMA patient-derived 
fibroblast cell line with dramatic downregulation of 
the SMN1 gene and significant downregulation of the 
GLE1 and MART3 gene expression. On the contrary, 
the FUS gene expression was found to be upregulated 
by three-fold in the SMA patient derived fibroblasts. 
The statistical analysis indicated that both MATR3 and 
GLE1 genes expression levels in fibroblast cell lines 
of type I SMA patient are not significant predictors 
of SMN1 gene expression level. However, FUS gene 
expression level in fibroblast cell lines of type I SMA 
patient was found to be a very significant predictor 
of SMN1 gene level expression. 
The various levels of aberrant gene expression are 
correlated and the characteristic of the dysregulation 
Figure 2. Prediction of the expression of FUS and MART3 
genes on SMN1 gene and protein expression. Multiple regres-
sion analysis was used to test if the SMN1 gene expression lev-
els significantly predicted expression of FUS (A) and MART3 
(B) proteins. A. Significant very strong positive correlation of 
SMN1 and FUS mRNAs is shown (p = 0.00001, R2 = 0.986). 
The diamond-shaped symbols represent SMN1 mRNA and 
square symbols predicted SMN1 protein levels. B. Moderate 
correlation between SMN1 and MART3 mRNAs was found 
(p = 0.005, R2 = 0.592). The diamond-shaped symbols rep-
resent SMN1 mRNA and square symbols predicted SMN1 
protein levels N = 3. 
A
B MART3 line fit plot
FUS line fit plot
S
M
N
1
S
M
N
1
MART3
FUS
SMN1
Predicted SMN1
SMN1
Predicted SMN1
0.0
2.6
0.0
0.0
0.002
0.002
0.004
0.004
0.006
0.006
0.2
2.7
0.4
2.8
0.6
2.9 3.0 3.1
0.8
3.2
219The expression of SMN1, MART3, GLE1 and FUS genes in spinal muscular atrophy
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2018
10.5603/FHC.a2018.0022
www.fhc.viamedica.pl
of mRNA processing proteins in various disease 
states [23]. Our study has confirmed dysregulated 
expression of the studied genes in SMA, which sug-
gests that these genes may play a role in the disease 
pathogenesis. Ultimately, these genes can serve as 
potential biomarkers and therapeutic targets to aid 
in disease diagnosis and treatment at the prenatal or 
new-born stage.
Interestingly, the marked downregulation of SMN1 
expression in the context of SMA in this study is in 
concert with the findings of the study by Lefebvre et 
al. (1995) [4] who first reported on SMN1 deficiency 
in SMA. This pioneer SMA study identified and 
characterized a 20 kb gene, now known to be a gene 
coding for SMN protein [4]. 
The interaction between FUS and SMN proteins 
in HeLa cells and different mouse tissues including 
the brain and spinal cord has been reported previously 
[24]. It was reported that ALS-linked FUS mutations 
altered the interaction between FUS and SMN [25]. 
The findings in our study showed that FUS is overex-
pressed in SMA fibroblasts, in accordance with the 
findings Mirra et al. [25]. This suggests that FUS has 
a molecular pathogenicity similar to SMN1 in causing 
SMA [25]. 
MART3 gene, on the other hand, has never been 
studied in the context of SMA patients, but it was 
proposed by Mirra et al. [25] to be implicated in SMA. 
The detected halved expression of MART3 in SMA 
fibroblasts in our experiment suggests that it has a role 
to play in SMA pathogenesis. The results of our study 
clearly show that the three genes are differentially 
expressed in the context of SMA. Thus, it is possible 
that these genes can be developed as biomarkers for 
SMA disease diagnosis and eventually, as targets of 
drug treatments against SMA. 
In this context it is worth to mention that Ogino et 
al. suggested that genetic testing is an essential com-
ponent of the proper management of SMA symptoms 
[3]. Thus, if we combine our findings with the current 
knowledge on SMA genetic dysregulation and include 
analysis of FUS and MART3 gene expression in the 
battery of biomarker tools used for SMA diagnosis, 
along with SMN1, increased SMA detection accuracy 
could be achieved. Moreover, if the roles of these 
mRNA processing proteins in SMA pathogenicity 
have been well defined and elucidated, the dependa-
bility factor in predicting SMA using these biomarkers 
will be much improved. Eventually, these findings and 
their potential applications in terms of diagnostics 
and therapy could help to manage and minimize the 
severity of the disease.
As suggested by Johnson et al. [9] and Gama-Car-
valho et al. [26], SMA and ALS have multiple links and 
shared abnormalities. These abnormalities are mostly 
based on the genetic changes in and dysregulation of 
their RNA processing proteins encoded by such genes 
as C9orf72, MART3 and FUS. Therefore, a wider in-
vestigation on the correlation of the ALS-associated 
genes and other neurodegenerative diseases-related 
genes is necessary.
The current study revealed by applying quantita-
tive real-time PCR that the dysregulated expression 
of SMA, MART3 and FUS was found within SMA 
patient-derived fibroblast cell-lines as compared to 
fibroblast of a healthy control. A similar approach can 
be adapted to study the putative proteins implicated 
in different motor neuron disorders such as ALS. 
Despite their stark similarities in neurodegeneration 
symptoms, different motor neuron diseases are de-
fined through different causative genetic lesion/s [26]. 
Thus, differences in the gene and protein expression 
profiles are expected to be obtained in different dis-
ease contexts.
While the exact disease pathogenesis for SMA 
due to mRNA dysregulation has still not been fully 
understood, dysfunctional gene expression can cause 
a broad range of disorders. In order to maintain the 
gene expression in specific cell states in humans it 
is controlled by thousands of cofactors, chromatin 
regulators and transcription factors. Moreover, tran-
scription dysfunction phenomena may hold clues as to 
the severity and onset of neuronal muscular disorders 
although this has not yet been conclusively deter-
mined. Nonetheless, the findings of the current study 
provide additional knowledge that can aid further 
investigations into the disease pathogenesis of SMA, 
and more importantly, a basis for clinical detection 
in individuals suspected to be at risk.
As presented by Marketou et al., GLE1 could be 
a promising gene therapy target to provide neuropro-
tection in infants with SMA [18]. Similarly, MART3 
and FUS must be studied further to obtain more 
information and ensure the credibility of the results 
before they can be used for in vivo clinical tests.
While numerous studies have attempted to pro-
vide a detailed background for understanding SMA 
pathogenicity [7, 26], our study has demonstrated an 
intriguing association between the differential gene 
expression of SMN1, MART3, and FUS in SMA that 
may contribute to the mechanisms of SMA patho-
genicity. 
Conclusions 
Our results emphasize the importance of hypothesis 
that changes of the RNA processing proteins play 
a key role in SMA pathomechanisms. Further studies 
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would show if these proteins can be used as mon-
itoring biomarkers early at the pregnancy stage to 
diagnose SMA and thus increase the survival rate if 
the treatment is available. 
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